Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Unified Patent Court

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

Indian pharma market set for ‘significant’ growth

Forecast to be worth $56bn by 2020, despite regulatory uncertainty

- PMLiVE

Teva defends Copaxone from Dutch patent challenge

Halts Mylan from marketing generic copy of MS drug

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

- PMLiVE

UK court upholds Teva’s patent on Copaxone

Dismisses challenge from Mylan

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

- PMLiVE

Setback for Teva as court dismisses Copaxone lawsuit

District Court dismisses claim that Mylan breached Teva’s patents on MS drug

- PMLiVE

US increases pressure on India over generics industry

Follows complaints from Pfizer about the country’s patent laws

- PMLiVE

Partial victory for biotech sector after gene patent ruling

US Supreme Court decides genes can be patented, if synthetically produced

- PMLiVE

Boehringer to restructure in Southern Europe

Closes chemical plant in France as part of plans to “adapt” business structure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links